NO924502L - Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser - Google Patents

Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser

Info

Publication number
NO924502L
NO924502L NO92924502A NO924502A NO924502L NO 924502 L NO924502 L NO 924502L NO 92924502 A NO92924502 A NO 92924502A NO 924502 A NO924502 A NO 924502A NO 924502 L NO924502 L NO 924502L
Authority
NO
Norway
Prior art keywords
piperazine
carboxamids
treatment
substance abuse
new use
Prior art date
Application number
NO92924502A
Other languages
English (en)
Other versions
NO924502D0 (no
NO301311B1 (no
Inventor
Anders Bjoerk
Erik Christensson
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of NO924502D0 publication Critical patent/NO924502D0/no
Publication of NO924502L publication Critical patent/NO924502L/no
Publication of NO301311B1 publication Critical patent/NO301311B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO924502A 1991-03-22 1992-11-23 Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser NO301311B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9100860A SE9100860D0 (sv) 1991-03-22 1991-03-22 New use
PCT/SE1992/000182 WO1992016211A1 (en) 1991-03-22 1992-03-23 New use of diphenylbutyl-piperazinecarboxamides in the treatment of substance disorders

Publications (3)

Publication Number Publication Date
NO924502D0 NO924502D0 (no) 1992-11-23
NO924502L true NO924502L (no) 1992-11-23
NO301311B1 NO301311B1 (no) 1997-10-13

Family

ID=20382242

Family Applications (1)

Application Number Title Priority Date Filing Date
NO924502A NO301311B1 (no) 1991-03-22 1992-11-23 Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser

Country Status (24)

Country Link
US (2) US5434156A (no)
EP (1) EP0538422B1 (no)
JP (1) JP3221611B2 (no)
KR (1) KR100196674B1 (no)
AT (1) ATE199057T1 (no)
AU (1) AU653797B2 (no)
BG (1) BG61829B1 (no)
BR (1) BR9204969A (no)
CA (1) CA2083505C (no)
CZ (1) CZ282222B6 (no)
DE (1) DE69231680T2 (no)
DK (1) DK0538422T3 (no)
EE (1) EE02973B1 (no)
ES (1) ES2154261T3 (no)
GR (1) GR3035805T3 (no)
HU (2) HU217833B (no)
IE (1) IE920920A1 (no)
NO (1) NO301311B1 (no)
PT (1) PT100279B (no)
RO (1) RO109702B1 (no)
RU (1) RU2095062C1 (no)
SE (1) SE9100860D0 (no)
SK (1) SK279237B6 (no)
WO (1) WO1992016211A1 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
JP3571114B2 (ja) * 1995-07-11 2004-09-29 ポーラ化成工業株式会社 麻薬拮抗剤
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6090780A (en) * 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
ZA200305922B (en) * 2001-01-17 2004-08-02 Hythiam Inc Use of flumazenil in developing a drug for the treatment of alcohol dependence.
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US7482365B2 (en) 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
NZ551340A (en) * 2004-04-22 2010-10-29 Boehringer Ingelheim Int Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006024471A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
JP2008540672A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
EP1945214A1 (en) * 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MX2008013827A (es) * 2006-05-09 2008-11-10 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual.
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
JP2009543839A (ja) * 2006-07-14 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 女性の性的障害を治療するためのフリバンセリンの使用
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
CN101505736A (zh) * 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放系统及其制造方法
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use

Also Published As

Publication number Publication date
ES2154261T3 (es) 2001-04-01
BR9204969A (pt) 1993-07-27
GR3035805T3 (en) 2001-07-31
US5618817A (en) 1997-04-08
JPH05507731A (ja) 1993-11-04
DE69231680D1 (de) 2001-03-15
HU217833B (hu) 2000-04-28
ATE199057T1 (de) 2001-02-15
BG61829B1 (bg) 1998-07-31
DK0538422T3 (da) 2001-05-07
HU9203632D0 (en) 1993-03-29
US5434156A (en) 1995-07-18
SK279237B6 (sk) 1998-08-05
RO109702B1 (ro) 1995-05-30
DE69231680T2 (de) 2001-06-07
BG97108A (bg) 1994-03-24
CA2083505C (en) 2003-06-10
CA2083505A1 (en) 1992-09-23
KR100196674B1 (ko) 1999-06-15
PT100279A (pt) 1993-07-30
AU653797B2 (en) 1994-10-13
IE920920A1 (en) 1992-09-23
NO924502D0 (no) 1992-11-23
RU2095062C1 (ru) 1997-11-10
CZ344992A3 (en) 1994-02-16
SE9100860D0 (sv) 1991-03-22
EP0538422B1 (en) 2001-02-07
AU1428092A (en) 1992-10-21
NO301311B1 (no) 1997-10-13
EP0538422A1 (en) 1993-04-28
CZ282222B6 (cs) 1997-06-11
JP3221611B2 (ja) 2001-10-22
HUT64696A (en) 1994-02-28
KR930700108A (ko) 1993-03-13
EE02973B1 (et) 1997-04-15
SK344992A3 (en) 1995-11-08
PT100279B (pt) 1999-06-30
WO1992016211A1 (en) 1992-10-01

Similar Documents

Publication Publication Date Title
NO924502D0 (no) Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser
NO931267D0 (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
BG97678A (en) Beta -carotene and/or vitamin e therapy for inhibition of major vascular events
EP1040830A4 (en) REMEDY FOR NEURODEGENERATIVE DISEASES
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
HUP0001063A2 (hu) Zöld porfirinek alkalmazása ateroszklerózis kezelésére szolgáló gyógyászati készítmények előállítására
DE3778008D1 (de) Ketonderivate als arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
AU5170499A (en) Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
KR100321319B1 (ko) 물질남용장애를치료하는방법및제약학적조성물
NO934832L (no) Farmasöytisk sammensetning for forhindring eller behandling av arterioscherose
SE9303612D0 (sv) New use
KR880009656A (ko) 국소 치근막 질환의 치료 또는 예방법
KR880012231A (ko) 스테로이드의 용도